According to IMARC Group latest report titled “T-cell Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a comprehensive analysis of the industry, which comprises insights on T-cell therapy market size. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global T-cell therapy market is expected to exhibit a growth rate (CAGR) of 16.3% during 2023-2028.

T-cell therapy, also known as adoptive cell transfer (ACT) therapy, is a type of immunotherapy that uses a patient's own immune cells, specifically T-cells, to attack cancer cells. It involves collecting T-cells from a patient's blood and modifying them in a laboratory to express chimeric antigen receptors (CARs) or T-cell receptors (TCRs) that recognize and bind to specific antigens in cancer cells. These modified T-cells are then expanded in number and infused into the patient's bloodstream, where they can locate and destroy cancer cells. Owing to these properties, T-cell therapy is widely adopted across hospitals and clinics across the globe.

 Request to Get the Sample Report: https://www.imarcgroup.com/t-cell-therapy-market/requestsample

Market Trends:

The market is primarily driven by the increasing prevalence of cancer due to the rising consumption of tobacco products, sedentary lifestyles, and unhealthy dietary patterns of individuals. In addition, the sudden spread of coronavirus disease (COVID-19) has escalated the adoption of T-cell therapies for treating high-risk patients, representing another major growth-inducing factor. Besides this, the implementation of government policies and regulations is also contributing the market growth. For instance, the United States Food and Drug Administration (USFDA) has approved the use of T-cell therapies to treat adults with advanced lymphomas and children with acute lymphoblastic leukemia (ALL), which is expected to create a positive market outlook in the coming years.

Explore Full Report with Table of Contents: https://www.imarcgroup.com/t-cell-therapy-market

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

  • Amgen Inc.
  • Aurora Biopharma Inc.
  • bluebird bio Inc
  • Bristol-Myers Squibb Company
  • Fate Therapeutics
  • Gilead Sciences Inc.
  • Merck KGaA
  • Mustang Bio Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sorrento Therapeutics Inc.
  • TCR2 Therapeutics

T-cell Therapy Market Segmentation:

Our report has categorized the market based on region, modality, therapy type and indication.

Breakup by Modality:

  • Research
  • Commercialized

Breakup by Therapy Type:

  • CAR T-cell based
  • T Cell Receptor (TCR) based
  • Tumor Infiltrating Lymphocytes (TIL) based

Breakup by Indication:

  • Hematologic Malignancies
    • Lymphoma
    • Leukemia
    • Myeloma
  • Solid Tumors
    • Melanoma
    • Brain and Central Nervous System
    • Liver Cancer
    • Others
  • Others

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

  • Market Performance (2017-2022)
  • Market Outlook (2023-2028)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe:- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800